SEARCH:   Advanced

Blood, 2 July 2009, Vol. 114, No. 1, pp. 144-147. Prepublished online as a Blood First Edition Paper on May 6, 2009; DOI 10.1182/blood-2009-03-210039. This Article Full Text (PDF) Supplemental Figures All Versions of this Article: blood-2009-03-210039v1 114/1/144    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Abdel-Wahab, O. Articles by Levine, R. L. Search for Related Content PubMed PubMed Citation Articles by Abdel-Wahab, O. Articles by Levine, R. L. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 11, 2009 Accepted April 27, 2009 Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Omar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, Guillermo Garcia-Manero, Jay Patel, Martha Wadleigh, Sebastien Malinge, JinJuan Yao, Outi Kilpivaara, Rukhmi Bhat, Kety Huberman, Sabrena Thomas, Igor Dolgalev, Adriana Heguy, Elisabeth Paietta, Michelle M. Le Beau, Miloslav Beran, Martin S. Tallman, Benjamin L. Ebert, Hagop M. Kantarjian, Richard M. Stone, D. Gary Gilliland, John D. Crispino, and Ross L. Levine* Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, United States Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States Montefiore Medical Center - North Division; New York Medical College, Bronx, NY, United States Section of Hematology/Oncology, University of Chicago, Chicago, IL, United States Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States Harvard Stem Cell Institute, Boston, MA, United States Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States * Corresponding author; email: leviner{at}mskcc.org. Disease alleles that activate signal transduction are common in myeloid malignancies, however there are additional unidentified mutations that contribute to myeloid transformation. Based on the recent identification of TET2 mutations we evaluated the mutational status of TET1, TET2, and TET3 in myeloproliferative neoplasms (MPN), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Sequencing of TET2 in 408 paired tumor/normal samples distinguished between 68 somatic mutations and 6 novel single nucleotide polymorphisms and to identify TET2 mutations in MPN (27/354: 7.6%), CMML (29/69 - 42%), AML (11/91 - 12%), and M7 AML (1/28 - 3.6%) samples. We did not identify somatic TET1 or TET3 mutations or TET2 promoter hypermethylation in MPN. TET2 mutations did not cluster in genetically defined MPN, CMML or AML subsets but were associated with decreased overall survival in AML (p=0.029). These data indicate TET2 mutations are observed in different myeloid malignancies and may be important in AML prognosis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: New GATA1 mutation in codon 2 leads to the earliest known premature stop codon in transient myeloproliferative disorder Sylvia Hoeller, Michel P. Bihl, Alexandar Tzankov, Thomas Kuehne, Christian Potthoff, and Elisabeth Bruder Blood 2009 114: 3717-3718. [Full Text] [PDF] This article has been cited by other articles: O. Kosmider, V. Gelsi-Boyer, M. Cheok, S. Grabar, V. Della-Valle, F. Picard, F. Viguie, B. Quesnel, O. Beyne-Rauzy, E. Solary, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) Blood, October 8, 2009; 114(15): 3285 - 3291. [Abstract] [Full Text] [PDF] A. Tefferi, K.-H. Lim, R. Levine, O. A. Bernard, and W. Vainchenker Mutation in TET2 in Myeloid Cancers N. Engl. J. Med., September 10, 2009; 361(11): 1117 - 1118. [Full Text] [PDF] C. Saint-Martin, G. Leroy, F. Delhommeau, G. Panelatti, S. Dupont, C. James, I. Plo, D. Bordessoule, C. Chomienne, A. Delannoy, et al. Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms Blood, August 20, 2009; 114(8): 1628 - 1632. [Abstract] [Full Text] [PDF] A. M. Jankowska, H. Szpurka, R. V. Tiu, H. Makishima, M. Afable, J. Huh, C. L. O'Keefe, R. Ganetzky, M. A. McDevitt, and J. P. Maciejewski Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms Blood, June 18, 2009; 113(25): 6403 - 6410. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020